• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

The promise of precision oncology

brought to life for patients

Join us in recognizing AML World Awareness Day and learn more about our commitment to advancing research and supporting the AML community.

View more in the Kura newsroom

The promise of precision oncology

brought to life for patients

KURA ANNOUNCES UPDATED CLINICAL DATA PRESENTED AT EHA 2023

Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed/Refractory NPM1-Mutated AML

SEE THE LATEST KOMET-001 DATA

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Our novel therapies are designed to target cancer cells selectively, increasing clinical benefit while moving the field forward in areas with the highest unmet needs. Just as vital to our mission, we’re investigating our novel therapies in combination with standards of care, forging new paths to give patients a better chance for long-term durable remissions.

We Are Kura

Our Commitment

We discover and develop novel cancer therapeutics that seek to improve patient outcomes and enable more patients to benefit.

About Us

Our Course

Through our evolving understanding of the molecular processes that drive cancer, we’re pioneering new approaches to treat devastating diseases, including head and neck cancer, lung cancer and acute leukemias.

Pipeline

Our Culture

We are courageous, science-driven innovators who work as one to create new possibilities for patients.

Careers

Our Heroes

Patients and caregivers: You are the “why” behind the work we do every day. Access resources and learn more about our approach.

Patients & Caregivers

Kura In The News

What pharma can teach biotech about the life cycle management of a drug

May 18, 2023/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/pharma_voice_gears.jpeg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2023-05-18 08:00:542023-05-23 13:57:17What pharma can teach biotech about the life cycle management of a drug

Navigating dose optimization requirements as a small biotech

February 1, 2023/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/BioCentury_0201_DB_DoseOptim.png 646 1246 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2023-02-01 08:00:002023-02-07 14:03:52Navigating dose optimization requirements as a small biotech

Liquid Biopsies Guide the Development of Cancer Drugs

September 6, 2022/in Currents

Liquid Biopsies Guide the Development of Cancer Drugs

Read more
https://kuraoncology.com/wp-content/uploads/LiquidBiopsies_GettyImages-1325872227-1068x712-1.jpg 712 1068 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2022-09-06 14:25:062023-01-05 12:40:46Liquid Biopsies Guide the Development of Cancer Drugs

Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready

June 28, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/troy_wilson_lab.png 478 850 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-06-28 12:00:192022-12-01 16:51:22Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready

ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations

April 21, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/AdobeStock_207889815-scaled.jpg 1709 2560 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-04-21 12:00:292022-11-16 13:32:04ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations

Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?

April 20, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/Kura_Dawn-of-Medicine-Article-img-scaled.jpeg 1709 2560 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-04-20 06:00:022022-11-16 13:25:55Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top
OSZAR »